Table 2.
Unpublished clinical trails(currently underway or completed without results available).
| Target (pathway) | Description with clinical trial identifier from ClinicalTrials.gov |
|---|---|
| Creatine (bioenergetics) | Several randomized controlled trials using creatine supplementation for TRD are currently underway. (NCT00729755, NCT01175616, NCT00313417, NCT00851006) NCT01601210 NCT02134808) |
| Ketamine (glutamate/NMDA) | Several other trials of ketamine for TRD are currently underway as interest grows in NMDA modulation (NCT01920555, NCT01304147, NCT01179009, NCT00768430, NCT01945047, NCT01627782, NCT01582945, NCT01613820). |
| Riluzole (glutamate) | Sanacora et al. are conducting a randomized, double-blind, placebo-controlled, 8 week trial of adjunctive riluzole for TRD (NCT01204918). |
| D-cycloserine (glutamate) | D-cycloserine, is a broad spectrum antibiotic that acts as a partial agonist at the NMDAR-associated GLY site. Randomized placebo controlled trial of conventional therapy with adjuvant with D-cycloserine, (up to 1 g/day) versus conventional therapy with placebo (NCT00408031). |
| EVT 101 (glutamate) | EVT101 is an orally active NR2B subtype-selective NMDA receptor antagonist. This clinical trial has been completed, however, no results have been published yet (NCT01128452). |
| GLYX-13 (IV) (glutamate) | GLYX-13 is an intravenous NMDA receptor glycine-site functional partial agonist. Clinical trial for TRD has been completed however no results have been published yet (NCT01234558). |
| RO4917523 (glutamate) | Trial assessed treatment of TRD with RO4917523,a mGluR5 allosteric antagonist however no results have been published yet (NCT01437657). |
| Buprenorphine (opioid) | Karp et al. has completed a double-blinded RCT of buprenorphine for TRD however results are currently unavailable (NCT01407575). |
| LY2456302 (opioid) | LY2456302 is a specific KOR antagonist currently being trialed for TRD in a double-blinded, placebo-controlled, proof-of-concept (POC) trial (NCT01913535). |
| Metyrapone (HPA axis) | Metyrpaone was assessed for TRD in a double-blinded, placebo-controlled twenty four week trial, however results have not yet been published (NCT01375920). |
| Oxytocin (HPA axis) | Intranasal oxytocin and tibolone are being trialed in a three-arm trial of oxytocin versus placebo versus oxytocin plus tibolone (NCT01239888). |
| Cysteamine (BDNF) | Cysteamine is a FDA approved agent for nephropathic cystinosis. It increases BDNF in the brain and promotes neuronal growth. Clinical trial for TRD has been terminated with no results available (NCT00715559). |
| Scopolamine + Ketamine (glutamate and muscarinic) | A combination intravenous injection of scopolamine with ketamine for TRD is currently being investigated in an open label trial (NCT01613820). |